SAN DIEGO, California, Nov. 01, 2022 – Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced it has entered into a sponsored research agreement with Michael Andreeff, M.D., Ph.D., Professor of Leukemia at The MD Anderson Cancer Center (“MD Anderson”). [Read more…]
Resolution Therapeutics and CCRM to develop and scale up manufacturing for iPSC-derived macrophage cell therapies
London, UK and Toronto, Canada 7 November, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, CCRM, one of the leading companies developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and OmniaBio Inc., CCRM’s subsidiary, today announced a research collaboration to develop and scale up a manufacturing platform for Resolution’s off-the-shelf iPSC-derived macrophage cell therapies. [Read more…]
Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development
San Francisco, CA, October 19, 2022 – Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories:
- Tempo-iBMEC™ – Human iPSC-derived Brain Microvascular Endothelial Cells
- Tempo-iPeri™ – Human iPSC-derived Pericytes
I Peace partners with the California Institute for Regenerative Medicine [CIRM]
PALO ALTO, Calif., Nov. 1, 2022 — I Peace, Inc. announced that the company has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing GMP Induced Pluripotent Stem Cells (iPSC) for a variety of cell therapy developers and pharmaceutical companies in the past several years and we believe this wonderful partnership with CIRM reflects the high-quality of our cell products and accompanying services. [Read more…]
3 PhD students from King’s College London win the $100,000 Stem Cell SpaceShot grant
Bordeaux, France, Cambridge (MA), USA / October 20th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced that an international team composed of 3 PhD students from King’s College London has been awarded the Stem Cell SpaceShot grant. With this $100,000 research funding, Matthew Wai Heng CHUNG, Cher Shen KIAR & Sofia SYNTAKA will explore the reprogramming of stem cell-derived macrophages, with the aim of repairing neuronal damage, such as spinal cord injury. [Read more…]
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 79
- Next Page »